SEC Form 4 · accession 0001209191-18-010949
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roberto Pedro Rosenkranz
Director
Period of report
Feb 15, 2018
Accepted (ET)
Feb 16, 2018 · 5:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2018 | M | 1,000 | $9.775 | A | 30,000 | D | |
| Common StockF2 | Feb 15, 2018 | S | 700 | $55.73 | D | 29,300 | D | |
| Common StockF3 | Feb 15, 2018 | S | 300 | $56.29 | D | 29,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $9.775 | Feb 15, 2018 | M | 1,000 | D | — | Apr 17, 2023 | Common Stock | 1,000 | 10,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 Plan.
- F2The shares were sold at prices ranging from $55.10 and $55.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $56.05 and $56.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Fully vested.